About 3,155 results

ALLMedicine™ Growth Hormone Deficiency Center

Research & Reviews  986 results

Clinical profile of Laron dwarfism - experience from a tertiary care institute in Chennai.
Journal of Pediatric Endocrinology & Metabolism : JPEM; Sethuraman C, Venkatasamy S

Mar 24th, 2023 - Laron dwarfism is a rare genetic disorder first reported among Israeli jewish children, subsequently about 350 cases cases have been reported worldwide. We aim to describe the clinical profile of nine children with Laron dwarfism from Institute of...

Benefits and risks evaluation of recombinant human growth hormone replacement therapy i...
Journal of Pediatric Endocrinology & Metabolism : JPEM; Pei LL, Guo Y et. al.

Mar 21st, 2023 - Childhood-onset craniopharyngiomas (CPs) have a high incidence of growth hormone deficiency (GHD) leading to growth failure and metabolic disorders. We aim to evaluate the benefits and risks of recombinant human growth hormone replacement therapy ...

Growth hormone after CNS tumor diagnosis: the fundamentals, fears, facts, and future di...
Pediatric Hematology and Oncology; Ronsley R, Lazow M et. al.

Mar 21st, 2023 - Growth hormone deficiency (GHD) may occur in pediatric patients with central nervous system (CNS) tumors at initial tumor presentation or later as treatment-related sequelae. While it is well recognized that growth hormone (GH) has beneficial effe...

Bone quality in endocrine diseases: determinants and clinical relevance.
Journal of Endocrinological Investigation; Cianferotti L, Cipriani C et. al.

Mar 16th, 2023 - Bone is one of the main targets of hormones and endocrine diseases are frequent causes of secondary osteoporosis and fractures in real-world clinical practice. However, diagnosis of skeletal fragility and prediction of fractures in this setting co...

Solitary median maxillary central incisor in Kabuki syndrome 2 with novel missense muta...
The Journal of Clinical Pediatric Dentistry; Rihani FB, Altayeh MM et. al.

Mar 10th, 2023 - Kabuki syndrome (KS) is an epigenetic machinery multisystem disorder with peculiar facial gestalt and dental-oral anomalies. This report describes the case of a KS patient with congenital hyperinsulinism, growth hormone deficiency and novel hetero...

see more →

Guidelines  1 results

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for Pr...
Neurosurgery Fleseriu M, Bodach ME et. al.

Sep 17th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present with hypopituitarism and/or hyperprolactinemia. To review the existing literature as it pertains to preoperative endocrine assessment in the work...

see more →

Drugs  14 results see all →

Clinicaltrials.gov  167 results

Metabolic and QOL Effects of GH Treatment in Patients With TBI and AGHD

Mar 6th, 2023 - Growth hormone replacement has consistently shown improvements in body composition, exercise capacity, endothelial function, inflammatory biomarkers, bone mineral density, lipoprotein metabolism, and self-reported quality of Life (QOL) in patients...

Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial

Mar 1st, 2023 - The TRIIM-X trial is an expanded pilot clinical study that will evaluate a personalized combination treatment regimen for thymus regeneration. The thymus is a part of the immune system that declines markedly with age, and regenerating it may preve...

A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information

Feb 21st, 2023 - In this study, the general long-term safety and effectiveness of Sogroya (somapacitan) in adults with growth hormone deficiency (AGHD) being treated per normal clinical practice is looked into. In the study, information on side effects and how wel...

Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)

Feb 16th, 2023 - There is significant overlap between the symptoms of adult growth hormone deficiency (AGHD) and those of Gulf War Illness (GWI) such as fatigue, chronic pain, depression, anxiety, and cognitive dysfunction. AGHD is also associated with metabolic c...

Growth Hormone Replacement Therapy for Retried Professional Football Players

Feb 8th, 2023 - GHD is the most common anterior pituitary abnormality after traumatic brain injury (TBI). It can occur as a result of either direct pituitary or indirect hypothalamic injury. Sports-related repetitive head trauma might induce pituitary dysfunction...

see more →

News  89 results

Second Biosimilar Insulin OK'd; Diabetes Risk After COVID; Omnipod DASH Recall

Nov 22nd, 2022 - The FDA approved the second interchangeable biosimilar insulin product, Eli Lilly's insulin glargine-aglr (Rezvoglar), for pediatric and adult patients with diabetes, the agency announced. Patients with diabetes and chronic kidney disease should b...

Diabetes Overtreated in Nursing Homes; Happy IVF Kids; Verapamil for Type 1 Diabetes

Mar 23rd, 2022 - In a study of 7,422 nursing home residents with type 2 diabetes, 17% met criteria for glycemic overtreatment and another 23% met criteria for potential overtreatment. (Journal of the American Geriatrics Society) Aeterna Zentaris announced some del...

More Positive Imcivree Data; ICER Reviews Tirzepatide; SGLT2 Inhibitors for Syncope?

Feb 20th, 2022 - Interim data from a long-term extension study of setmelanotide (Imcivree) for pediatric and adult patients with Bardet-Biedl Syndrome found an average BMI reduction of 14.3% from baseline and a 14.9% drop in body weight, Rhythm Pharmaceuticals ann...

Infectious and Back at Work; FDA May Limit Some Monoclonals; 'Done With COVID'?

Jan 24th, 2022 - Note that some links may require registration or subscription. Strained hospitals are calling potentially infectious healthcare workers back to their posts, citing the CDC's latest guidance. (Washington Post) NIAID Director Anthony Fauci, MD, said...

FDA Approves First Once-Weekly Growth Hormone for Children

Sep 2nd, 2021 - The US Food and Drug Administration (FDA) has approved lonapegsomatropin (Skytrofa, Ascendis Pharma), the first weekly subcutaneous injectable growth hormone for children with growth hormone deficiency (GHD). The approval was based on the findings...

see more →

Patient Education  5 results see all →